WiCON | Pharma China (Web Edition)

ONLINE ENQUIRY

WiCON International Group
21 Bridge Street
Metuchen, NJ 08840, USA
Tel/Fax: +1 801-751-5728
info@pharmachinaonline.com

Affiliated Companies
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com

BJ Jicai PharmTech
Oriental Kenzo Plaza
Beijing, China
Tel: +86 10 84476010
info@pharmachinaonline.com

Review of Chinese Pharma Deals, R&D and Regulatory Developments in 2020 The annual review summarizes the important events, including M&A, JV, licensing, R&D partnership deals, new drug R&D projects and new regulations, which are recorded in P...
(2/23/2021)

CANbridge Pharma and Puma Biotech Agree to Te... (2/25/2021)

Biosecurity Law of the P.R.C. - Full Text Unof... (2/25/2021)

PharmaNJ's China NMPA Approved Tracker: Jan 20... (2/25/2021)

PharmaDJ's China Licensing Deals Tracker: Jan ... (2/23/2021)

Review of Chinese Pharma Deals, R&D and Regula... (2/23/2021)

The Race to the Top: Does China Have What It T... (2/22/2021)

How Foreign Companies Can Break Into China's B... (2/22/2021)

NLR: China's Patent Office Releases Draft Meas... (2/9/2021)

SCMP: Phase One Trade Deal Largely A "Failure"... (2/9/2021)

Kantar: Chinese Physicians' Digital Behaviour ... (2/8/2021)

Changes To Biotech And Chemical Patent Examina... (2/4/2021)

AJMC: China Pulls Out Stops for Biosimilar Dev... (2/3/2021)

CANbridge Pharma and Puma Biotech Agree... (2/26/2021) Spring Promotion - Pharma China Publicat... (2/26/2021) (Free) NMPA Announces Package Insert Revision o... (2/26/2021) Recent Executive Moves (2/26/2021) Financial-related Company News in Brief (2/26/2021) 241 A Share-Listed Chinese MedPharm Cos ... (2/26/2021) Harbour BioMed Announces Chinese IND App... (2/25/2021) Puma Biotech and Pierre Fabre Amend NERL... (2/25/2021) China Approves Two More Domestic COVID-1... (2/25/2021) (Free) Snapshot of BMI System Financial Perform... (2/25/2021) AstraZeneca Gains Default Chinese IND Ap... (2/25/2021) CDE Seeks Comments on Implementation Adv... (2/25/2021) CDE Issues the Technical Guidelines for ... (2/25/2021) Gannex Receives U.S. IND Approval for TH... (2/24/2021) Kuehne+Nagel Forms Strategic Partnership... (2/24/2021) Snapshot of MNC Products in the 2020 NRD... (2/24/2021) Review of Chinese Import Chemical Drug I... (2/24/2021) Graviton Enters into Global Licensing Ag... (2/23/2021)

IHS Markit: China Pharma in the Year of the Ox Anticancer Medicines in China: Trends in Daily Therapy ... NH Reports on Chinese OTC Eye Care Market in MAT 09/202... NH Reports Latest Data on Chinese Smoking Control Marke... NH Reports on Chinese OTC Sleep Aids Market in MAT 09/2...

241 A Share-Listed Chinese MedPharm Cos Release 2020 Pe... Financial-related Company News in Brief CANbridge Pharma and Puma Biotech Agree to Terminate N... Puma Biotech and Pierre Fabre Amend NERLYNX License Dea... Snapshot of MNC Products in the 2020 NRDL

NMPA Announces Package Insert Revision of Misoprostol T... CDE Issues the Technical Guidelines for Non-clinical St... CDE Seeks Comments on Implementation Advice on ICH Guid... Review of Chinese Import Chemical Drug IND Applications... NMPA Issues the List of Reference Formulations for GQCE...

Snapshot of BMI System Financial Performance in 2020 China Further Promotes TCM Development by Strengthening... State Council Issues the Regulation on the Use of Medic... IQVIA Conducts Survey of Physician Behaviors at the Int... NHSA Issues Two Documents for Inter-provincial Direct S...

Wyeth Wins Trademark Infringement and Unfair Competiti... Boehringer Sues China's Qilu Pharma in the U.S. over Pa... Bayer's Nexavar Composition Patent Challenged and Inval... Bayer: Successfully Protected Legal Rights of "Kangwang... USTR Unleashes 2020 Report for China's WTO Compliance H...

Indian Pharma Firms Go Local Seeking to End Reliance on... India Probes Alleged API Dumping by Chinese Companies China Increases Prices of Key Drug Ingredients by Up To... U.S. Introduces A 'Buy American First' Pharma Executive... Fitch: No Near-Term Impact on Chinese API Makers as Pha...

AstraZeneca Gains Default Chinese IND Approval for Its ... China Approves Two More Domestic COVID-19 Vaccines Harbour BioMed Announces Chinese IND Approval of for Co... Gannex Receives U.S. IND Approval for THR-β Agonist AS... Junshi Bio Announces sNDA Acceptance for Toripalimab C...

BioAtla and BeiGene Revise Global Deal for Novel Condit... Pfizer to Absorb Mylan, Creating Global Generic Powerho... PhRMA Calls for Trade Deals That Force Countries to Pay... IQVIA: Global Pharma to Grow Slower in the Next Five Ye... Pfizer and GSK Announce JV to Create a Global Consumer ...

Recent Executive Moves Recent Executive Moves Recent Executive Moves Former UF Professor Indicted for Defrauding NIH and Co... Recent Executive Moves

Spring Promotion - Pharma China Publications Spring Promotion - Pharma China publications U.S. Chamber Releases In-Depth Analysis of U.S.-China E... Upcoming Event: Plenareno Pharma Middle East Virtual Co... Live Podcast - VC & Impact Investing in China: Investin...

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

Pharma China on Twitter and Faceboo... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON to Hold Pharma China Annual F... WiCON Publishes the China Pharmaceu...